A RetroSearch Logo

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Search Query:

Showing content from https://en.wikipedia.org/wiki/Edivoxetine below:

Edivoxetine - Wikipedia

From Wikipedia, the free encyclopedia

Chemical compound

Pharmaceutical compound

Edivoxetine (INN; code name LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment.[1][2] It was in phase III clinical trials in 2012 for major depressive disorder, but failed to get approval.[1][3]

In a study published in 2010, edivoxetine succeeded to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology.[4]

In a study published in 2011, using the Montgomery–Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates.[5]

In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials.[6]

Side effects significantly associated with edivoxetine are headache, nausea, constipation, dry mouth and insomnia.[4]

The above-mentioned studies report increases of the cardiac rhythm, and one also increases of diastolic and systolic blood pressures.[4][5]

  1. ^ a b Jun Yan (March 2012). "Pipeline for new antidepressants flowing slowly". Psychiatric News. 47 (5): 1b–29. doi:10.1176/pn.47.5.psychnews_47_5_1-b. Retrieved 2012-04-27 – via American Psychiatric Association.
  2. ^ "Statement on a nonproprietary name adopted by the USAN council - Edivoxetine" (PDF) (Press release). American Medical Association. 2012. Retrieved 2012-04-12.
  3. ^ Chancellor D (November 2011). "The depression market". Nature Reviews. Drug Discovery. 10 (11): 809–10. doi:10.1038/nrd3585. PMID 22037032. S2CID 3194093.
  4. ^ a b c Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P (April 2010). "A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression". Journal of Psychiatric Research. 44 (6): 356–363. doi:10.1016/j.jpsychires.2009.09.013. PMID 19909980.
  5. ^ a b Pangallo P, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C (June 2011). "A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder". Journal of Psychiatric Research. 45 (6): 748–755. doi:10.1016/j.jpsychires.2011.03.014. PMID 21511276.
  6. ^ "Lilly Announces Edivoxetine Did Not Meet Primary Endpoint of Phase III Clinical Studies as Add-On Therapy for Major Depressive Disorder | Eli Lilly and Company".
Monoamine reuptake inhibitors DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors) NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors) SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors) VMATsTooltip Vesicular monoamine transporters Others See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.4